Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855848 | 0.77 | ALDH1A1 (0.42) | CA12CA1CA2CA9NPC1 | |
| SCHEMBL16815477 | 0.75 | RAB9A (0.41) | HTR2AHTR2CSLC6A4NPC1RAB9A | |
| SCHEMBL24914911 | 0.74 | HTR2C (0.40) | HTR2CSLC6A4 | |
| SCHEMBL2586635 | 0.74 | MTOR (0.42) | NPC1RAB9A | |
| SCHEMBL23163271 | 0.73 | GRM2 (0.36) | NPC1RAB9A | |
| SCHEMBL25332567 | 0.73 | NPC1 (0.32) | NPC1RAB9A | |
| SCHEMBL14762382 | 0.73 | DRD2 (0.46) | HTR2ANPC1RAB9A | |
| SCHEMBL24013561 | 0.73 | NPC1 (0.36) | NPC1RAB9A | |
| SCHEMBL14762377 | 0.73 | NPC1 (0.32) | NPC1RAB9A | |
| SCHEMBL411068 | 0.71 | ACHE (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755952-B1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | HOFFMANN LA ROCHE (CH) | 2016-03-30 | — | — | EP | disclosed |
| EP-2755952-B1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | HOFFMANN LA ROCHE (CH) | 2016-03-30 | — | — | EP | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| EP-2613785-B1 | HETEROARYLMETHYL AMIDES | HOFFMANN LA ROCHE (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090599-B2 | Heteroarylmethyl amides | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2755952-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2013037721-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037721-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194436-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | HTR2A 1456/4885HTR2C 2296/4885SLC6A4 4323/4885 |
| US-20130065907-A1 | 5-CYCLOALKYL- OR 5-HETEROCYCLYL-NICOTINAMIDES | NNT, APOB, LDLR | HTR2A 2867/4885HTR2C 3260/4885SLC6A4 2557/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | HTR2A 1456/4885HTR2C 2296/4885SLC6A4 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.